1,861,020 Shares in Solventum Corporation $SOLV Purchased by Norges Bank

Norges Bank acquired a new position in Solventum Corporation (NYSE:SOLV) in the fourth quarter, HoldingsChannel.com reports. The institutional investor acquired 1,861,020 shares of the company’s stock, valued at approximately $147,467,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LSV Asset Management increased its position in Solventum by 364.5% in the third quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after purchasing an additional 27,561 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Solventum by 15.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after purchasing an additional 40,812 shares during the period. Davis Selected Advisers increased its position in Solventum by 0.5% in the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after purchasing an additional 24,950 shares during the period. Appleton Partners Inc. MA acquired a new stake in Solventum in the fourth quarter worth about $7,008,000. Finally, SG Americas Securities LLC increased its position in Solventum by 92.3% in the fourth quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after purchasing an additional 44,970 shares during the period.

Solventum Price Performance

Solventum stock opened at $78.39 on Thursday. The firm has a market capitalization of $13.58 billion, a P/E ratio of 9.61, a PEG ratio of 1.18 and a beta of 0.69. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $88.20. The business has a 50-day moving average of $70.21 and a 200-day moving average of $75.12. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Insider Activity

In other Solventum news, Director Amy Mcbride Wendell acquired 1,475 shares of the firm’s stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on SOLV. UBS Group lowered Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a research report on Thursday, May 14th. Stifel Nicolaus decreased their target price on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $89.00 target price on shares of Solventum in a research report on Wednesday, May 6th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Wells Fargo & Company decreased their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $84.25.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.